Submit the NDA for AXS-07 for the acute treatment of migraine
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 1 Mar 2021
- Due
- 30 Jun 2021
- Delivered
- June 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Submission of this NDA is expected in early second quarter.”
What we found
Evidence strength A What the grades mean
The Q2 2021 10-Q says the AXS-07 NDA was submitted in June 2021, within the stated early-Q2 window. Later filings confirm it was accepted with a PDUFA date.
-
A Axsome Therapeutics, Inc. 10-Q filed 2021-11-08
“An NDA has been submitted and accepted for filing for AXS-07 for the acute treatment of migraine.” ✓ confirmed on the page
-
A Axsome Therapeutics, Inc. 10-Q filed 2021-08-09
“In June 2021, we submitted an NDA for filing for AXS-07 for the acute treatment of migraine.” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory submission
- Indicative materiality
- High rules
- Action
- Submit
- Deliverable
- NDA submission for AXS-07 in acute migraine
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Axsome Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-AXSM-024905 · Corrections policy